Inhaled corticosteroids in children with asthma: Pharmacologic determinants of safety and efficacy and other clinical considerations

Pediatric Drugs

Volumn 9, Issue 3, 2007, Pages 185-194

  Gulliver, Tanya ^a   Morton, Ronald ^b   Eid, Nemr ^b  

^a JOHN HUNTER CHILDREN S HOSPITAL   (Australia)

^b University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHLOROFLUOROCARBON; CICLESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DEXAMETHASONE; FATTY ACID; FLUNISOLIDE; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE; GLUCOCORTICOID; MOMETASONE FUROATE; MONTELUKAST; NEDOCROMIL; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; PRODRUG; PROPELLANT; SALMETEROL; THEOPHYLLINE; TRIAMCINOLONE;

ADRENAL SUPPRESSION; AEROSOL; ANXIETY DISORDER; ASTHMA; CLINICAL TRIAL; DISEASE MARKER; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; ESTERIFICATION; EXPIRATORY RESERVE VOLUME; GASTROINTESTINAL SYMPTOM; GROWTH INHIBITION; GROWTH RATE; HEADACHE; HUMAN; HYPOPHYSIS; INFLAMMATION; LIPOPHILICITY; LIVER CLEARANCE; LONGITUDINAL STUDY; LOW DRUG DOSE; LUNG BLOOD VESSEL; LUNG DEPOSIT; LUNG FUNCTION; META ANALYSIS; MONOTHERAPY; PARTICLE SIZE; PHARMACODYNAMICS; PHARMACOGENETICS; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; REVIEW; SIDE EFFECT; SOLUTION AND SOLUBILITY; SUSPENSION; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ASTHMA; CHILD; HUMANS;

EID: 34249826656     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200709030-00007     Document Type: Review

References (104)

1. Masoli M, Fabian D, Holt S, et al. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59: 469-78
2. National Center for Health Statistics. Faststats: asthma [online]. Available from URL: http://www.cdc.gov/nchs/faststats/asthma/htm [Accessed 2007 Feb 9]
3. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics: 2002. J Allergy Clin Immunol 2002; 110 (5 Suppl.): S141-219
4. Davies RJ, Stampone P, O'Connor BJ. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose. Respir Med 1998; 92 Suppl. A: 23-31
5. Micheletto C, Guerriero M, Tognella S, et al. Effects of HFA- and CFC-beclomethasone dipropionate on the bronchial response to methacholine (MCh) in mild asthma. Respir Med 2005; 99: 850-5
6. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998; 12 (6): 1346-53
7. Thorsson L, Dahlstrom K, Edsbacker S, et al. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1997; 43 (2): 155-61
8. Leach CL, Davidson PJ, Hasselquist BE, et al. Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone from a metered dose inhaler. J Aerosol Med 2005; 18 (4): 379-85
9. Whelan GJ, Blumer JL, Martin RJ, et al. Fluticasone propionate plasma concentration and systemic effect: effect of delivery device and duration of administration. J Allergy Clin Immunol 2005; 116 (3): 525-30
10. Daley-Yates PT, Price AC, Sisson JR, et al. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 2001; 51 (5): 400-9
11. Ryrfeldt A, Andersson P, Edsbacker S, et al. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis Suppl 1982; 122: 86-95
12. Mackie AE, Ventresca GP, Fuller RW, et al. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1996; 41 (6): 539-42
13. Nave R, Bethke TD, van Marle SP, et al. Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects. Clin Pharmacokinet 2004; 43 (7): 479-86
14. Rohatagi S, Arya V, Zech K, et al. Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol 2003; 43 (4): 365-78
15. Mitchell JP, Nagel MW, Archer AD. Size analysis of a pressurized metered dose inhaler-delivered suspension formulation by the API Aerosizer time-of-flight aerodynamic particle size analyzer. J Aerosol Med 1999; 12 (4): 255-64
16. Waugh J, Goa KL. Flunisolide HFA. Am J Respir Med 2002; 1 (5): 369-72; discussion 373
17. Kunka R, Andrews S, Pimazzoni M, et al. From hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs. Respir Med 2000; 94 Suppl. B: S10-6
18. Leach CL, Bethke TD, Boudreau RJ, et al. Two-dimensional and three-dimensional imaging show ciclesonide has high lung deposition and peripheral distribution: a nonrandomized study in healthy volunteers. J Aerosol Med 2006; 19 (2): 117-26
19. Thorsson L, Edsbacker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 1994; 7 (10): 1839-44
20. Richter K, Kanniess F, Biberger C, et al. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol 2005; 45 (2): 146-52
21. Leach CL, Davidson PJ, Hasselquist BE, et al. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest 2002; 122 (2): 510-6
22. Boobis AR. Comparative physicochemical and pharmacokinetic profiles of inhaled beclomethasone dipropionate and budesonide. Respir Med 1998; 92 Suppl. B: 2-6
23. Affrime MB, Cuss F, Padhi D, et al. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol 2000; 40 (11): 1227-36
24. Dickens GR, Wermeling DP, Matheny CJ, et al. Pharmacokinetics of flunisolide administered via metered dose inhaler with and without a spacer device and following oral administration. Ann Allergy Asthma Immunol 2000; 84 (5): 528-32
25. Mollmann H, Wagner M, Krishnaswami S, et al. Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. J Clin Pharmacol 2001; 41 (12): 1329-38
26. Pickering H, Pitcairn GR, Hirst PH, et al. Regional lung deposition of a technetium 99m-labeled formulation of mometasone furoate administered by hydrofluoroalkane 227 metered-dose inhaler. Clin Ther 2000; 22: 1483-93
27. Schering-Plough Ltd. Asmanex twisthaler (mometasone furoate dry powder inhaler). Welwyn Garden City: Schering-Plough Ltd, 2004
28. Nolting A, Sista S, Abramowitz W. Flunisolide HFA vs flunisolide CFC: pharmacokinetic comparison in healthy volunteers. Biopharm Drug Dispos 2001; 22 (9): 373-82
29. Crim C, Pierre LN, Daley-Yates PT. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther 2001; 23 (9): 1339-54
30. Kelly HW. Comparative potency and clinical efficacy of inhaled corticosteroids. Respir Care Clin N Am 1999; 5 (4): 537-53
31. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 1997; 91 Suppl. A: 22-8
32. Dietzel K, Engelstätter R, Keller A, et al. Ciclesonide: an on-site activated steroid. In: Hansel TT, Barnes PJ, editors. New drugs for asthma, allergy and COPD. Basel: Karger, 2001: 91-3
33. Corren J, Nelson H, Greos LS, et al. Effective control of asthma with hydrofluoroalkane flunisolide delivered as an extrafine aerosol in asthma patients. Ann Allergy Asthma Immunol 2001; 87 (5): 405-11
34. Marshall BG, Wangoo A, Harrison LI, et al. Tumour necrosis factor-alpha production in human alveolar macrophages: modulation by inhaled corticosteroid. Eur Respir J 2000; 15 (4): 764-70
35. Hauber HP, Gotfried M, Newman K, et al. Effect of HFA-flunisolide on peripheral lung inflammation in asthma. J Allergy Clin Immunol 2003; 112 (1): 58-63
36. Ederle K, Multicentre Study Group. Improved control of asthma symptoms with a reduced dose of HFA-BDP extrafine aerosol: an open-label, randomised study. Eur Rev Med Pharmacol Sci 2003; 7 (2): 45-55
37. Thongngarm T, Silkoff PE, Kossack WS, et al. Hydrofluoroalkane-134A beclomethasone or chlorofluorocarbon fluticasone: effect on small airways in poorly controlled asthma. J Asthma 2005; 42 (4): 257-63
38. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994; 88 (5): 373-81
39. Zeiger RS, Dawson C, Weiss S. Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP). J Allergy Clin Immunol 1999; 103 (3 Pt 1): 376-87
40. Long-term effects of budesonide or nedocromil in children with asthma: the Childhood Asthma Management Program Research Group. N Engl J Med 2000; 343 (15): 1054-63
41. Ulrik CS, Backer V. Markers of impaired growth of pulmonary function in children and adolescents. Am J Respir Crit Care Med 1999; 160 (1): 40-4
42. Brown PH, Blundell G, Greening AP, et al. Screening for hypothalamo-pituitary-adrenal axis suppression in asthmatics taking high dose inhaled corticosteroids. Respir Med 1991; 85 (6): 511-6
43. Lipworth BJ, Seckl JR. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax 1997; 52 (5): 476-82
44. Brocklebank D, Wright J, Cates C. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. BMJ 2001; 323 (7318): 896-900
45. Thorsson L, Edsbacker S. Lung deposition of budesonide from a pressurized metered-dose inhaler attached to a spacer. Eur Respir J 1998; 12 (6): 1340-5
46. Howarth PH. Why particle size should affect clinical response to inhaled therapy. J Aerosol Med 2001; 14 Suppl. 1: S27-34
47. Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf 2000; 23 (1): 11-33
48. Lipworth BJ, Jackson CM. Pharmacokinetics of chlorofluorocarbon and hydrofluoroalkane metered-dose inhaler formulations of beclomethasone dipropionate. Br J Clin Pharmacol 1999; 48 (6): 866-8
49. Martin RJ, Szefler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 2002; 165 (10): 1377-83
50. Brutsche MH, Brutsche IC, Munawar M, et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 2000; 356 (9229): 556-61
51. Harrison TW, Tattersfield AE. Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects. Thorax 2003; 58 (3): 258-60
52. Griffioen RW, de Jongh FH. Inhalation therapy in children younger than two years. Ned Tijdschr Geneeskd 1998; 142: 1484-8
53. Hubner M, Hochhaus G, Derendorf H. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am 2005; 25 (3): 469-88
54. Hochhaus G. New developments in corticosteroids. Proc Am Thorac Soc 2004; 1 (3): 269-74
55. Miller-Larsson A, Axelsson B-O, Brattsand R, et al. Relative lipophilicity of budesonide, fluticasone propionate, mometasone furoate, and ciclesonide: preference of variable lipophilicity in airways versus systemic compartment [abstract]. Am J Respir Crit Care Med 2003; 167 (7): A773
56. Nave R, Fisher R, Zech K. In vitro metabolism of ciclesonide in human lung and liver precision-cut tissue slices. Biopharm Drug Dispos 2006; 27 (4): 197-207
57. Tunek A, Sjodin K, Hallstrom G. Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes. Drug Metab Dispos 1997; 25 (11): 1311-7
58. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med 1998; 157 (3 Pt 2): S1-53
59. Mollmann H, Wagner M, Meibohm B, et al. Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. Eur J Clin Pharmacol 1998; 53 (6): 459-67
60. Wilson AM, Dempsey OJ, Coutie WJ, et al. Importance of drug-device interaction in determining systemic effects of inhaled corticosteroids. Lancet 1999; 353 (9170): 2128
61. Derendorf HH, Machhaus G. The effect of protein binding on adrenal suppression potential of inhaled corticosteroids. J Allergy Clin Immunol 2006; 117 (2): s94
62. Schering-Plough Ltd. Asmanex twisthaler (mometasone furoate dry powder inhaler) SPC. Welwyn Garden City: Schering-Plough Ltd, 2004
63. Szefler SJ. Pharmacokinetics of intranasal corticosteroids. J Allergy Clin Immunol 2001; 108 (1 Suppl.): S26-31
64. Fardon TC, Lee DK, Haggart K, et al. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Respir Crit Care Med 2004; 170 (9): 960-6
65. Hogger P, Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 1994; 59: 597-602
66. Masoli M, Weatherall M, Holt S, et al. Systematic review of the dose-response relation of inhaled fluticasone propionate. Arch Dis Child 2004; 89 (10): 902-7
67. Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 2003; 348 (6): 538-49
68. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348 (6): 529-37
69. Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002; 109 (3): 410-8
70. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br Med Bull 2000; 56 (4): 1054-70
71. Weiss ST, Litonjua AA, Lange C, et al. Overview of the pharmacogenetics of asthma treatment. Pharmacogenomics J 2006; 6 (5): 311-26
72. Lazarus SC, Boushey HA, Fahy JV, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001; 285 (20): 2583-93
73. Chowdhury B. Division director memorandum: overview of FDA background materials prepared for the meeting to discuss the implications of the available data related to the safety of long-acting beta-agonist bronchodilators, June 15, 2005 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/05/ briefing/2005-4148B1_03_01-FDA-Div-Dir-Memo.pdf [Accessed 2006 Jun]
74. The FDA safety information and adverse event reporting program: 2003 safety alert: Serevent (salmeterol xinofoate) [online]. Available from URL: in http://www.fda.gov/medwatch/SAFETY/2003/serevent.htm [Accessed 2006 Jun]
75. Bisgaard H. Effect of long-acting beta2 agonists on exacerbation rates of asthma in children. Pediatr Pulmonol 2003; 36 (5): 391-8
76. Bisgaard H. Long-acting beta(2)-agonists in management of childhood asthma: a critical review of the literature. Pediatr Pulmonol 2000; 29 (3): 221-34
77. Verberne AA, Frost C, Roorda RJ, et al. One year treatment with salmeterol compared with beclomethasone in children with asthma: the Dutch Paediatric Asthma Study Group. Am J Respir Crit Care Med 1997; 156 (3 Pt 1): 688-95
78. Simons FE. A comparison of beclomethasone, salmeterol, and placebo in children with asthma: Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group. N Engl J Med 1997; 337 (23): 1659-65
79. Reed CE, Offord KP, Nelson HS, et al. Aerosol beclomethasone dipropionate spray compared with theophylline as primary treatment for chronic mild-to-moderate asthma: the American Academy of Allergy, Asthma and Immunology Beclomethasone Dipropionate-Theophylline Study Group. J Allergy Clin Immunol 1998; 101 (1 Pt 1): 14-23
80. Leflein JG, Szefler SJ, Murphy KR, et al. Nebulized budesonide inhalation suspension compared with cromolyn sodium nebulizer solution for asthma in young children: results of a randomized outcomes trial. Pediatrics 2002; 109 (5): 866-72
81. Garcia Garcia ML, Wahn U, Gilles L, et al. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics 2005; 116 (2): 360-9
82. National Institutes of Health, National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program: quick reference. NAEPP Expert Panel report guidelines for the diagnosis and management of asthma update on selected topics 2002. J Allergy Clin Immunol 2002; 110 (5 Suppl.): S141-219
83. Lipworth BJ, Kaliner MA, LaForce CF, et al. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 2005; 94 (4): 465-72
84. Buhl R, Vinkler I, Magyar P, et al. Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma. Pulm Pharmacol Ther 2006; 19 (6): 404-12
85. Limb SL, Brown KC, Wood RA, et al. Irreversible lung function deficits in young adults with a history of childhood asthma. J Allergy Clin Immunol 2005; 116 (6): 1213-9
86. O'Byrne PM, Pedersen S, Busse WW, et al. Effects of early intervention with inhaled budesonide on lung function in newly diagnosed asthma. Chest 2006; 129 (6): 1478-85
87. Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006; 354 (19): 1985-97
88. Brown PH, Blundell G, Greening AP, et al. Hypothalamo-pituitary-adrenal axis suppression in asthmatics inhaling high dose corticosteroids. Respir Med 1991; 85 (6): 501-10
89. Bisgaard H, Damkjaer Nielsen M, Andersen B, et al. Adrenal function in children with bronchial asthma treated with beclomethasone dipropionate or budesonide. J Allergy Clin Immunol 1988; 81 (6): 1088-95
90. Burch WM. Urine free-cortisol determination: a useful tool in the management of chronic hypoadrenal states. JAMA 1982; 247 (14): 2002-4
91. Derendorf H, Hochhaus G. What is the best marker for inhaled corticosteroid safety? Allergy Asthma Proc 2005; 26 (2): 89-93
92. Nelson HS, Stricker W, Casale TB, et al. A comparison of methods for assessing hypothalamic-pituitary-adrenal (HPA) axis activity in asthma patients treated with inhaled corticosteroids. J Clin Pharmacol 2002; 42 (3): 319-26
93. Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med 2006; 100 (8): 1307-17
94. Oelkers W. Adrenal insufficiency. N Engl J Med 1996; 335 (16): 1206-12
95. Todd GR, Acerini CL, Ross-Russell R, et al. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002; 87 (6): 457-61
96. Reynolds NA, Scott LJ. Ciclesonide. Drugs 2004; 64 (5): 511-9; discussion 520-1
97. Weinbrenner A, Huneke D, Zschiesche M, et al. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab 2002; 87 (5): 2160-3
98. Postma DS, Sevette C, Martinat Y, et al. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J 2001; 17 (6): 1083-8
99. Rees L, Rigden SP, Chantler C. The influence of steroid therapy and recombinant human erythropoietin on the growth of children with renal disease. Pediatr Nephrol 1991; 5 (4): 556-8
100. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976; 51 (3): 170-9
101. Silverstein MD, Yunginger JW, Reed CE, et al. Attained adult height after childhood asthma: effect of glucocorticoid therapy. J Allergy Clin Immunol 1997; 99 (4): 466-74
102. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000; 343 (15): 1064-9
103. Eid NS. Update on National Asthma Education and Prevention Program pediatric asthma treatment recommendations. Clin Pediatr (Phila) 2004; 43 (9): 793-802
104. Boulet LP. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest 1998; 113 (3): 587-92